Cancer BiologybioRxivPreprint
A fluorescence-based sensor screen identifies MED12 as a potential microsatellite instability regulator in colon cancer
DOI 10.1101/2023.08.17.553681
Author
R. Beijersbergen
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2018-2023 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 30 mutual co-author linksFocal author (center)Selected co-authorORCID co-authorUnlinked name
Curved chords = mutual co-authorship5 papers
Recent·Most cited
- Cancer BiologybioRxiv
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator
A. Zaalberg, E. Minnee, I. Mayayo-Peralta…·A. M. Bergman
This study uses a CRISPR screen to identify genes critical for macrophage-mediated killing of prostate cancer cells, revealing AR as an immunomodulator that promotes resistance to macrophage attack.
DOI 10.1038/s41388-026-03912-8 - Cancer BiologybioRxiv
Paradoxical activation of oncogenic signaling as a cancer treatment strategy
M. H. Dias, A. Friskes, S. Wang…·R. Bernards
This study shows that inhibiting PP2A and WEE1 together can kill colon cancer cells by causing DNA replication collapse and cell death, and that resistance to this treatment suppresses tumor growth.
DOI 10.1158/2159-8290.cd-23-0216 - Cancer BiologybioRxivPreprint
Glucocorticoids regulate cancer cell dormancy
S. Prekovic, K. Schuurman, A. Gonzalez Manjon…·W. Zwart
This study identifies the mechanism by which glucocorticoid receptor activation induces cancer cell dormancy through CDKN1C and FOXO1/IRS2 signaling, with implications for cancer therapy.
DOI 10.1101/750406 - Cancer BiologybioRxiv
phospho-ERK is a response biomarker to a combination of sorafenib and MEK inhibition in liver cancer
R. R. Bernards, C. Wang, H. Jin…·W.-X. Qin
This study identifies phospho-ERK as a biomarker for response to sorafenib and MEK inhibition in liver cancer, showing synergistic effects in tumors with high phospho-ERK levels.
DOI 10.1016/j.jhep.2018.07.004